Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.

Authors:
Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA and 8 more

Journal:
J Clin Virol

Publication Year: 2022

DOI:
10.1016/j.jcv.2022.105328

PMCID:
PMC9651991

PMID:
36399969

Journal Information

Full Title: J Clin Virol

Abbreviation: J Clin Virol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Virology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors declare that they have no conflicts of interest."

Evidence found in paper:

"Funding This work was supported by Medigen Vaccine Biologics Corporation (award number: XMRPG3L0101) and Chang Gung Memorial Hospital (award numbers: CORPG3K0311, CORPG3L0371, CORPG3L0481, and CORPG3K0242), Taiwan. The study was also supported in part by the Research Center for Epidemic Prevention Science, Chang Gung University (award number: MOST 109–2327-B-182–002), Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Trial registrationClinicalTrials.gov NCT05132855."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025